
Fulltext:
170299.pdf
Embargo:
until further notice
Size:
941.0Kb
Format:
PDF
Description:
publisher's version
Publication year
2017Source
Expert Review of Vaccines, 16, 4, (2017), pp. 329-336ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Medical Microbiology
Journal title
Expert Review of Vaccines
Volume
vol. 16
Issue
iss. 4
Page start
p. 329
Page end
p. 336
Subject
Radboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences; Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life SciencesAbstract
INTRODUCTION: Malaria is a devastating vector-borne disease caused by the Plasmodium parasite, resulting in almost 0.5 million casualties per year. The parasite has a complex life-cycle that includes asexual replication in human red blood cells, causing symptomatic malaria, and sexual stages which are essential for the transmission to the mosquito vector. A vaccine targeting the sexual stages of the parasite and thus blocking transmission will be instrumental for the eradication of malaria. One of the leading transmission blocking vaccine candidates is the sexual stage antigen Pfs48/45. Areas covered: PubMed was searched to review the progress and future prospects for clinical development of a Pfs48/45-based subunit vaccine. We will focus on biological function, naturally acquired immunity, functional activity of specific antibodies, sequence diversity, production of recombinant protein and preclinical studies. Expert commentary: Pfs48/45 is one of the lead-candidates for a transmission blocking vaccine and should be further explored in clinical trials.
This item appears in the following Collection(s)
- Academic publications [202713]
- Electronic publications [100828]
- Faculty of Medical Sciences [79990]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.